A new anticancer agent (LY186641) interferes with creatinine assay.
The administration of a diarylsulfonylurea, LY186641, which is presently undergoing a multicentric phase I clinical trial as an anticancer agent, produces major analytical interference with commonly used creatinine analysis techniques. We confirm that this interference is caused by a metabolite rather than the parent compound and propose an alternative, interference-free method.
Bonnay
M M
MM
Département de Biologie Clinique, Institut Gustave-Roussy, Villejuif,France.
Recondo
G
G
Gouyette
A J
AJ
Armand
J P
JP
D000970:Antineoplastic Agents / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood*; D006801:Humans; D013453:Sulfonylurea Compounds / Q000494:pharmacology*
D000970:Antineoplastic Agents; D013453:Sulfonylurea Compounds; D003404:Creatinine; C058179:sulofenur